Recombinant Human B7-H3 Fc Chimera Protein, CF | R&D Systems 1027-B3-100 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human B7-H3 Fc Chimera Protein, CF

catalog :

1027-B3-100

quantity :

100 ug

price :

443 USD

citations: 10

Reference
Sun Y, Maggs L, Panda A, Wright S, Cicerchia A, Jenney A, et al. TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids. Cancer Immunol Res. 2025;13:210-228 pubmed publisher
Xu J, Chen H, Xu P, You X, Zhu G, Gao F. Clinical significance of B7-H3 expression in circulating CD4+CD25high T cells, CD14+ monocytes, and plasma for the progression of HIV infection. BMC Infect Dis. 2023;23:462 pubmed publisher
Li H, Harrison E, Li H, Hirabayashi K, Chen J, Li Q, et al. Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration. Nat Commun. 2022;13:2154 pubmed publisher
Grosskopf A, Labanieh L, Klysz D, Roth G, Xu P, Adebowale O, et al. Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors. Sci Adv. 2022;8:eabn8264 pubmed publisher
Zebley C, Abdelsamed H, Ghoneim H, Alli S, Brown C, Haydar D, et al. Proinflammatory cytokines promote TET2-mediated DNA demethylation during CD8 T cell effector differentiation. Cell Rep. 2021;37:109796 pubmed publisher
Zhang Y, He L, Sadagopan A, Ma T, Dotti G, Wang Y, et al. Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells. Mol Cancer Ther. 2021;20:577-588 pubmed publisher
Vogl U, Ohler L, Rasic M, Frischer J, Modak M, Stockl J. Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy. Anticancer Res. 2017;37:1947-1955 pubmed
Yoon B, Chung Y, Yoo S, Kawara K, Kim J, Yoo I, et al. Preferential Induction of the T Cell Auxiliary Signaling Molecule B7-H3 on Synovial Monocytes in Rheumatoid Arthritis. J Biol Chem. 2016;291:4048-57 pubmed publisher
Zhang G, Wang J, Kelly J, Gu G, Hou J, Zhou Y, et al. B7-H3 augments the inflammatory response and is associated with human sepsis. J Immunol. 2010;185:3677-84 pubmed publisher
Crispen P, Sheinin Y, Roth T, Lohse C, Kuntz S, Frigola X, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008;14:5150-7 pubmed publisher

product information

master code :

1027-B3

SKU :

1027-B3-100

product name :

Recombinant Human B7-H3 Fc Chimera Protein, CF

unit size :

100 ug

description :

The Recombinant Human B7-H3 Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Human B7-H3 Fc Chimera Protein, CF has been validated for the following applications: Bioactivity.

target :

B7-H3

category :

Proteins and Enzymes

buffer :

Lyophilized from a 0.2 ╡m filtered solution in PBS.

conjugate :

Unconjugated

purity :

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining.

species :

Human

observed molecular weight :

70-80 kDa, reducing conditions

theoretical molecular weight :

50 kDa (monomer)

gene symbol :

CD276

details of functionality :

Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated human T cells. The ED50 for this effect is 3-12 ╡g/mL. Optimal dilutions should be determined by each laboratory for each application.

endotoxin note :

<0.10 EU per 1 ╡g of the protein by the LAL method.

accessionNumbers :

NP_079516

applications :

Bioactivity

source long :

Mouse myeloma cell line, NS0-derived human B7-H3 protein Human B7-H3 (Leu29-Pro245) Accession # NP_079516 DIEGRMD Human IgG1 (Pro100-Lys330) N-terminus C-terminus

source short :

NS0

USD :

443 USD

alt names :

B7H3, B7H34Ig-B7-H3, B7-H3B7 homolog 3, CD276, CD276 antigen, CD276 molecule, Costimulatory molecule

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.